All In Biotech

Drug Trial Radar · NCT05657184

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

An Open-label Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 for Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 19, 2021

Primary completion

Jun 9, 2023

Study completion Jun 9, 2023

Sponsor

Lead sponsor
Regend TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Peking Union Medical College Hospital; Ruijin Hospital; The First Affiliated Hospital of Guangzhou Medical University; Regend Therapeutics XLotus (Jiangxi) Co, Ltd.
First posted
Dec 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • REGEND001Drug

    Transplantation of REGEND001 for dose escalation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of the cell therapy-related adverse events (AEs)Time frame: Within 24 weeks after treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.